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Abstract
TRIM5 is a potent retrovirus inhibitor that targets viruses bearing particular capsid (CA) residues.
In most primate species, retroviral restriction requires the C-terminal SPRY domain unique to the
α -isoform of TRIM5, but the mechanism by which susceptible viruses are recognized and targeted
for restriction is unknown. Here we show that TRIM5α  binds retroviral CA from detergent-
stripped virions in a SPRY-dependent manner with sufficient discrimination to account for the
exquisite specificity of restriction.
Findings
Two independent screens identified TRIM5 as a potent ret-
rovirus restriction element that targets select viruses after
entry into primate cells [1,2]. The biochemical basis for
specificity of restriction is only evident in cells of the owl
monkey where HIV-1 CA is recognized by the C-terminal
cyclophilin domain that is unique to the TRIM5 ortho-
logue found in this genus [2-4]. In all other primates,
including humans and macaques, potent CA-specific
restriction is conferred by the TRIM5α  isoform [1,5-9],
which possesses a C-terminal SPRY domain [10]. The
mechanism by which TRIM5α  selects retroviruses bearing
particular CAs for restriction is unknown, though the
TRIM5α  SPRY domain is required for restriction and vari-
ation in SPRY amino acid residues determines the CA-spe-
cificity of given TRIM5α  orthologues [9,11-13].
Conventional biochemical and two-hybid experiments
failed to detect an interaction between TRIM5α  and CA
(SS and JL, unpublished data). The observation that non-
infectious virus-like particles saturate TRIM5α -mediated
restriction [14], but only if the particles bear a mature core
from a restriction-sensitive virus [15,16] suggests that the
TRIM5α  SPRY domain recognizes a complex structure
unique to the core of susceptible virions. Consistent with
this model, expression within target cells of gag, gag-pol, or
gag fragments encoding CA, CA-NC, or ubiquitin-CA-NC
fusions, failed to block restriction activity (David Sayah
and JL, unpublished data).
Retrovirion cores can be liberated from the viral mem-
brane envelope by detergent [17]. HIV-1 virion cores were
prepared with several different detergents and mixed with
recombinant TRIM5 orthologues. After TRIM5 enrich-
ment by affinity chromatography, CA associated with owl
monkey TRIMCypA, as reported with other methods
[3,4], but not with the equally potent HIV-1 restriction
factor rhesus macaque TRIM5α  (SS and JL, unpublished
data).
We then selected murine leukemia virus (MLV) for study
because, relative to HIV-1, MLV CA remains tightly associ-
ated with viral reverse transcription (RT) and preintegra-
tion complexes [18,19]. MLV strains bearing an arginine
at CA residue 110 (so-called N-MLV) are highly suscepti-
ble to restriction by human TRIM5α  whereas MLV virions
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bearing glutamate in this position (B-MLV) are com-
pletely resistant to restriction [5-8].
VSV G-pseudotyped N- and B-tropic MLV virions were
produced as previously described [20] and, after normali-
zation on non-restrictive Mus dunni cells, N-MLV was
roughly 100-fold less infectious than B-MLV on HeLa cells
(Figure 1A). Full-length human TRIM5α  was then pro-
duced as a GST-fusion protein in 293T cells and mixed
with purified N-MLV virions. CAp30, the major MLV core
protein constituent, associated with TRIM5α  (Figure 1B).
CAp30 from B-MLV virions did not associate with
TRIM5α  (Figure 1B) demonstrating that TRIM5α  binding
was specific for restriction-sensitive CA. CAp30 did not
associate with TRIM5 lacking the SPRY domain (Figure
1B), indicating that the SPRY-domain is required for CA-
recognition.
Retroviral restriction specificity thus seems to be deter-
mined by TRIM5α  binding to CA in a process that requires
the SPRY domain. The fact that TRIM5α  recognized retro-
viral CA presented by detergent-stripped virion cores, but
not free CA protein, suggests that the SPRY domain recog-
nizes a complex surface of multimerized CA. Once cores
of restriction-sensitive viruses are singled out by the SPRY
domain, TRIM5α  blocks retroviral RT [1] by a mechanism
that awaits elucidation. Our findings bring us one step
closer to understanding how the potent antiviral activity
of TRIM5α  might be harnessed to block HIV-1 infection
in people.
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Human TRIM5α  binds CA from restricted MLV virions Figure 1
Human TRIM5α  binds CA from restricted MLV virions. (A) 
HeLa cells were infected with VSV G-pseudotyped, N- and B-
tropic MLV-GFP vectors after normalization for RT activity 
and infectivity on non-restrictive Mus dunni tail fibroblasts. 
The percentage of infected (GFP-positive) cells was deter-
mined by flow cytometry. (B) 293T cells were transfected 
with plasmids encoding glutathione S-transferase (GST) 
fusions with full-length TRIM5α  or with TRIM5 lacking the 
SPRY domain. Cells were lysed (50 mM Tris pH 8.0, 150 mM 
NaCl, 1% NP-40, 0.1% SDS) and mixed for 2 hrs at 4°C with 
virions (N-MLV or B-MLV) that had been concentrated by 
acceleration through 25% sucrose. GST fusions and associ-
ated proteins were enriched on glutathione-sepharose beads 
and immunoblotted with goat anti-MLV CA antibody (CA 
pull-out), or anti-GST antibody (bottom panel). Unbound CA 
remaining in the binding reaction was probed with anti-MLV 
CA antibody (CA input). TRIM5 protein domains fused to 
GST are indicated schematically on the bottom left: RF, ring 
finger; BB, B box; CC, coiled-coil.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2005, 2:40 http://www.retrovirology.com/content/2/1/40
Page 3 of 3
(page number not for citation purposes)
2. Sayah DM, Sokolskaja E, Berthoux L, Luban J: Cyclophilin A retro-
transposition into TRIM5 explains owl monkey resistance to
HIV-1. Nature 2004, 430(6999):569-573.
3. Nisole S, Lynch C, Stoye JP, Yap MW: A Trim5-cyclophilin A
fusion protein found in owl monkey kidney cells can restrict
HIV-1. Proc Natl Acad Sci U S A 2004, 101(36):13324-13328.
4. Berthoux L, Sebastian S, Sayah DM, Luban J: Disruption of human
TRIM5alpha antiviral activity by nonhuman primate
orthologues. J Virol 2005, 79(12):7883-7888.
5. Keckesova Z, Ylinen LM, Towers GJ: The human and African
green monkey TRIM5alpha genes encode Ref1 and Lv1 ret-
roviral restriction factor activities. Proc Natl Acad Sci U S A 2004,
101(29):10780-10785.
6. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD:
Retrovirus resistance factors Ref1 and Lv1 are species-spe-
cific variants of TRIM5alpha.  Proc Natl Acad Sci U S A 2004,
101(29):10774-10779.
7. Yap MW, Nisole S, Lynch C, Stoye JP: Trim5alpha protein
restricts both HIV-1 and murine leukemia virus. Proc Natl Acad
Sci U S A 2004, 101(29):10786-10791.
8. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J:
TRIM5alpha mediates the postentry block to N-tropic
murine leukemia viruses in human cells. Proc Natl Acad Sci U S
A 2004, 101(32):11827-11832.
9. Song B, Javanbakht H, Perron M, Park do H, Stremlau M, Sodroski J:
Retrovirus restriction by TRIM5alpha variants from old
world and new world primates. J Virol 2005, 79(7):3930-3937.
10. Ponting C, Schultz J, Bork P: SPRY domains in ryanodine recep-
tors (Ca(2+)-release channels).  Trends Biochem Sci 1997,
22(6):193-194.
11. Yap MW, Nisole S, Stoye JP: A single amino acid change in the
SPRY domain of human Trim5alpha leads to HIV-1
restriction. Curr Biol 2005, 15(1):73-78.
12. Sawyer SL, Wu LI, Emerman M, Malik HS: Positive selection of pri-
mate TRIM5alpha identifies a critical species-specific retro-
viral restriction domain.  Proc Natl Acad Sci U S A 2005,
102(8):2832-2837.
13. Stremlau M, Perron M, Welikala S, Sodroski J: Species-Specific
Variation in the B30.2(SPRY) Domain of TRIM5{alpha}
Determines the Potency of Human Immunodeficiency Virus
Restriction. J Virol 2005, 79(5):3139-3145.
14. Towers G, Collins M, Takeuchi Y: Abrogation of Ref1 retrovirus
restriction in human cells. J Virol 2002, 76(5):2548-2550.
15. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger
HG, Bieniasz PD: Cellular inhibitors with Fv1-like activity
restrict human and simian immunodeficiency virus tropism.
Proc Natl Acad Sci U S A 2002, 99(18):11914-11919.
16. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD:
Cyclophilin A modulates the sensitivity of HIV-1 to host
restriction factors. Nat Med 2003, 9(9):1138-1143.
17. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Krausslich HG:
Biochemical and structural analysis of isolated mature cores
of human immunodeficiency virus type 1.  J Virol 2000,
74(3):1168-1177.
18. Bowerman B, Brown PO, Bishop JM, Varmus HE: A nucleoprotein
complex mediates the integration of retroviral DNA. Genes
Dev 1989, 3(4):469-478.
19. Fassati A, Goff SP: Characterization of intracellular reverse
transcription complexes of Moloney murine leukemia virus.
J Virol 1999, 73(11):8919-8925.
20. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, Danos O: A con-
served mechanism of retrovirus restriction in mammals. Proc
Natl Acad Sci U S A 2000, 97(22):12295-12299.